FAKTOR-OPTIONSSCHEIN - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 01:15:35 18/05/2024 am IST | ||
| 0.24 EUR | 0.00% |
|
| Current month | -4.00% | ||
| 1 month | -17.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.24 | 0.00% |
| 16/24/16 | 0.24 | +4.35% |
| 15/24/15 | 0.23 | -8.00% |
| 14/24/14 | 0.25 | -3.85% |
| 13/24/13 | 0.26 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 18, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SN2V8F |
| ISIN | DE000SN2V8F4 |
| Date issued | 03/06/2022 |
| Strike | 311.1 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.72 € |
|---|---|
| Lowest since issue | 0.22 € |
| Spread | 0.01 € |
| Spread % | 4.00% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- Certificat
